ALDACTONE (spironolactone)
HYPERTENSION·+6
PHARMACIA/UPJHN
Indication
Aldosteronism
Aldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone. Read more about Aldosteronism
32 drugs 32 manufacturers
Drugs that treat it
Common Aldosteronism therapies.
SPIRONOLACTONE
DIURETICS·HYPERTENSION·+6
MUTUAL PHARM CO
SPIRONOLACTONE
DIURETICS·HYPERTENSION·+6
Mylan Pharmaceuticals
SPIRONOLACTONE
DIURETICS·HYPERTENSION·+6
Amneal Pharmaceuticals
SPIRONOLACTONE
HYPERTENSION·+6
RICHMOND PHARM
SPIRONOLACTONE
DIURETICS·HYPERTENSION·+6
GREENSTONE LLC.
SPIRONOLACTONE
HYPERTENSION·+6
QUALITEST
SPIRONOLACTONE
HYPERTENSION·+6
ACTAVIS ELIZABE
SPIRONOLACTONE
DIURETICS·HYPERTENSION·+6
MYLAN INSTITUTI
Filter & compare in the drug finder →Opens the drug finder with Aldosteronism preselected.
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonAldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone.
It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system.
Pathophysiologically, sustained hyperaldosteronism promotes excessive renal sodium reabsorption and potassium excretion, producing plasma volume expansion, systemic hypertension—frequently resistant to conventional antihypertensive therapies—and variable degrees of hypokalemia and metabolic alkalosis.
Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke.
- medlineplus.gov
Aldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system
- nih.gov
Aldosteronism, also termed hyperaldosteronism, is an endocrine disorder characterized by excessive secretion of the mineralocorticoid hormone aldosterone It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system Pathophysiologically, sustained hypera...
- clevelandclinic.org
It primarily impacts the cardiovascular and renal systems and is categorized into primary forms, caused by autonomous adrenal pathology such as bilateral adrenal hyperplasia or aldosterone-producing adenomas, and secondary forms driven by extra-adrenal activation of the renin-angiotensin-aldosterone system
- endocrine.org
Pathophysiologically, sustained hyperaldosteronism promotes excessive renal sodium reabsorption and potassium excretion, producing plasma volume expansion, systemic hypertension—frequently resistant to conventional antihypertensive therapies—and variable degrees of hypokalemia and metabolic alkalosis
- merckmanuals.com
Pathophysiologically, sustained hyperaldosteronism promotes excessive renal sodium reabsorption and potassium excretion, producing plasma volume expansion, systemic hypertension—frequently resistant to conventional antihypertensive therapies—and variable degrees of hypokalemia and metabolic alkalosis
- nih.gov
Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke
- nih.gov
Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke
- endocrine.org
Left unmanaged, the chronic mineralocorticoid excess substantially increases the risk of target-organ damage, including adverse cardiovascular events, chronic kidney disease, and stroke
Personalize your experience
Follow Aldosteronism and get updates as they land.
Create a free account
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.